Impact of pathologic re-review on grade, clinical stage, and risk stratification for patients with nonmuscle invasive bladder cancer

•Pathologic grade and stage define non-muscle invasive bladder cancer risk groups.•Pathology re-review changed grade and/or stage in 21% of patients with NMIBC.•TURBT pathology re-review may change risk group and management for some patients. Pathologic re-review of transurethral resection of bladde...

Full description

Saved in:
Bibliographic Details
Published in:Urologic oncology 2024-11, Vol.42 (11), p.372.e21-372.e27
Main Authors: Campbell, Rebecca A., Wood, Andrew, Michael, Patrick D., Shin, David, Pramod, Nikhil, Haywood, Samuel C., Eltemamy, Mohamed, Weight, Christopher, Haber, Georges-Pascal, Lee, Byron, Myles, Jonathan, McKenney, Jesse, Nguyen, Jane, Williamson, Sean R., Przybycin, Christopher, Alaghehbandan, Reza, Almassi, Nima
Format: Article
Language:English
Subjects:
Non-muscle-invasive bladder cancer
Pathologic grade
Risk stratification
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Pathologic grade and stage define non-muscle invasive bladder cancer risk groups.•Pathology re-review changed grade and/or stage in 21% of patients with NMIBC.•TURBT pathology re-review may change risk group and management for some patients. Pathologic re-review of transurethral resection of bladder tumor (TURBT) specimen is a common practice at our tertiary care center, but its impact on disease risk stratification remains unknown. We sought to determine how pathologic re-review of specimen initially read at an outside institution changed grade, clinical T (cT) stage, and AUA non-muscle-invasive bladder cancer (NMIBC) risk stratification. The laboratory information system was searched for patients who underwent TURBT from 2021 to 2022, yielding 561 records. 173 patients met inclusion criteria: 113 with
ISSN:1078-1439
1873-2496
1873-2496
DOI:10.1016/j.urolonc.2024.05.020